Daijiro Harada

6PUBLICATIONS
25CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jan 02, 2024
Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study).

Shinji Nakamichi, Kaoru Kubota, Toshihiro Misumi

|Aug 14, 2023
Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study).

Yusuke Okuma, Shogo Nomura, Kiichiro Ninomiya

|Nov 20, 2022
Safety of anti-SARS-CoV-2 messenger RNA vaccine in lung cancer patients undergoing anticancer chemotherapy: A multicenter, prospective, observational, patient-reported outcome study.

Daijiro Harada, Tomoki Tamura, Kiichiro Ninomiya

|Jun 10, 2022
Early administration of durvalumab after chemoradiotherapy increased risk of pneumonitis in patients with locally advanced non-small cell lung cancer.

Daijiro Harada, Atsushi Shimonishi, Kazuhiko Saeki

|Nov 27, 2021
Oligoprogression in Non-Small Cell Lung Cancer.

Daijiro Harada, Nagio Takigawa

|Apr 03, 2019
A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement.

Daijiro Harada, Toshiyuki Kozuki, Naoyuki Nogami

Pageof 1

Frequent Collaborators

2 joint publications

Shuji Murakami

2 joint publications

Hiroaki Okamoto

1 joint publications

Nagio Takigawa

1 joint publications

Tomoki Tamura